Processing

Please wait...

Settings

Settings

Goto Application

1. CU24362 - DERIVADOS DE 1,2,4-OXADIAZOL COMO INMUNOMODULADORES

Office
Cuba
Application Number 2016000029
Application Date 05.09.2014
Publication Number 24362
Publication Date 04.10.2018
Publication Kind B1
IPC
A61K 31/4245
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4245Oxadiazoles
A61K 31/433
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
433Thiadiazoles
C07D 271/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
271Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
02not condensed with other rings
061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
C07D 285/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
285Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/-C07D283/183
01Five-membered rings
02Thiadiazoles; Hydrogenated thiadiazoles
04not condensed with other rings
081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
CPC
A61K 31/433
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
433Thidiazoles
C07D 273/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
273Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
08having two nitrogen atoms and more than one oxygen atom
A61K 31/4245
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
4245Oxadiazoles
C07D 271/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
271Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
02not condensed with other rings
061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
A61K 31/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
C07D 273/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
273Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
Applicants AURIGENE DISCOVERY TECHNOLOGIES LTD.
Inventors Naremaddepalli, Seetharamaiah Setty Sudarshan
Ramachandra, Muralidhara
Sasikumar, Pottayil Govidan Nair
Priority Data 4011/CHE/2013 06.09.2013 IN
Title
(ES) DERIVADOS DE 1,2,4-OXADIAZOL COMO INMUNOMODULADORES
Abstract
(ES)

La presente invención se refiere a compuestos 1,2,4-oxadiazol y 1,2,4-tiadiazol como agentes terapéuticos capaces de inhibir la vía de señalización de la muerte celular programada 1 (PD1). La invención además se refiere a derivados de los agentes terapeúticos. La invención además abarca el uso de dichos agentes terapeúticos y derivados para el tratamiento de los trastornos a través de inmunopotenciación que comprende la inhibición de la señal inmunosupresiva inducida debido a PD-1, PD-L1 ó PD-L2 y las terapias donde se usan.